logo-loader
RNS
International Biotechnology Trust Plc

Intnl. Biotechnology - Dividend Declaration

RNS Number : 0555L
Intl. Biotechnology Trust PLC
06 July 2026
 

6 July 2026

 

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

 

Second interim dividend for the year ending 31 August 2026

 

At the Annual General Meeting of International Biotechnology Trust plc (the "Company") held on 12 December 2025, shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4% of the Company's net asset value as at the last day of the preceding financial year (31 August 2025), through two equal semi-annual distributions.

 

The Directors have declared the payment of a second interim dividend of 15.67 pence per ordinary share for the year ending 31 August 2026.

 

In addition, the Company paid the first interim dividend of 15.64 pence per ordinary share for the year ending 31 August 2026 on 23 January 2026.

 

As at 3 July 2026, the latest practicable date prior to publication of this announcement, an annual dividend of 31.31 pence per share represents a yield of 2.86% calculated with reference to the Company's closing share price of 1,095 pence that day.

  

Ex-dividend date:

23 July 2026

Record date:

24 July 2026

Payment date:

21 August 2026

Dividend per share:

15.67 pence

 

 

Enquiries:

Michelle Taiwo/Natalia de Sousa

Schroder Investment Management Limited

Tel: 020 7658 6000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVRJMLTMTJMBIF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

IBT portfolio manager: biotech M&A boom set to continue as big pharma hunts

International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a...

on 07/10/2026

2 min read